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Abstract. Background/Aim: To search for new antileukemic
agents, the chemical structure of phenytoin was modified.
A possible cytotoxic activity of three bromoalkyl phenytoin
analogs, methyl 2-(1-(3-bromopropyl)-2,4-dioxo-5,5-
diphenylimidazolidin-3-yl) propanoate (PH2), 1-(3-
bromopropyl)-3-methyl-5,5-diphenylimidazolidine-2,4-
dione (PH3) and 1-(4-bromobutyl)-3-methyl-5,5-
diphenylimidazolidine-2,4-dione (PH4) on regulated cell
death, the cell cycle and cell ultrastructure was assessed.
Materials and Methods: The experiments were performed in
vitro on HL-60 and U937 cells, using flow cytometry and
electron microscopy methods. Results: Application of PH2,
PH3, and PH4 resulted in cell surface exposure of
phosphatidylserine and plasma membrane impairment,
caspase-8, -9, and -3/7 activation, dissipation of mitochondrial
membrane potential, DNA breakage, cell-cycle disturbance and
cell ultrastructural changes. In general, PH3 appeared to be
the most active against the leukemia cells, and all bromoalkyl
hydantoins, PH2-PH4, were more active in HL-60 cells than
in U937 cells. Conclusion: The antileukemic activity of the
bromoalkyl phenytoin analogs depended on the combination of
N-hydantoin substituents and the human cell line used.
Phenytoin molecule (5,5-diphenylhydantoin, 5,5-diphenyli-
midazolidine-2,4-dione) is known as an anticonvulsant and
antiarrhythmic drug (1, 2) but it is also an interesting structure
for chemical modifications to obtain new biologically-active
compounds that act on therapeutically important proteins, e.g.
serotonin- (3) or adrenergic (4) receptors as well as on
multidrug resistance (MDR) proteins in bacteria (5, 6) and
cancer cells (7, 8). Due to the structural similarity to the known
non-steroidal antiandrogen nilutamide (5,5-dimethyl-3-(4-nitro-
3-(trifluoromethyl)phenyl) hydantoin) used in therapy of
prostate cancer (9), phenytoin seems to be also an interesting
starting point in search for new anticancer agents. Nevertheless,
available information on their cytotoxic action on pathological
cells is scarce (7, 8, 10-12). 
Recently, phenytoin derivatives with or without alkyl chain
at the position 1 of hydantoin and methyl or ester substituent
at the position 3, including methyl 2-(2,4-dioxo-5,5-
diphenylimidazolidin-3-yl)propanoate (PH1), methyl 2-(1-(3-
bromopropyl)-2,4-dioxo-5,5-diphenylimidazolidin-3-
yl)propanoate (PH2), 1-(3-bromopropyl)-3-methyl-5,5-
diphenylimidazolidine-2,4-dione (PH3) and 1-(4-bromobutyl)-
3-methyl-5,5-diphenylimidazolidine-2,4-dione (PH4), were
synthesized. Their structures were elected as probably
cytotoxic in pathological cells based on the toxicology training
in silico, and using OSIRIS bioinformatics tools
(http://www.organic-chemistry.org/prog/ peo/). The results of
previous in vitro studies confirmed this hypothesis, showing
that PH1, PH2, PH3, and PH4 affected leukemia cells viability,
volume and count (13). Among these four agents, the
phenytoin derivative PH1 without bromoalkyl substituent
appeared to be less active against leukemia cells than the
bromoalkyl phenytoin analogs, PH2, PH3 and PH4 (Figure 1).
To our knowledge, there are no published data on triggering
regulated cell death (14) and causing changes in cell cycle and
cell ultrastructure by the bromoalkyl phenytoin analogs, PH2,
PH3, and PH4. Therefore, understanding the mechanisms of
action of these 5,5-diphenylhydantoin derivatives against
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pathological cells is of great importance in determining their
anticancer potential. 
The aim of the present study was to assess and compare the
in vitro antileukemic activity of PH2, PH3 and PH4. To
determine the mechanisms of their action on human leukemia
cells, their influence on plasma membrane diversity and
integrity, caspase activation, mitochondrial membrane
potential, DNA damage, the cell cycle and cell ultrastructure,
was analyzed.
Materials and Methods
Cells. The experiments were carried out on human promyelocytic
leukemia HL-60 and human histiocytic lymphoma U937 cells obtained
from American Type Culture Collection (Rockville, MD, USA). The
cells were maintained in RPMI 1640 medium (Gibco BRL Life
Technologies, Waltham, MA, USA) supplemented with 10% fetal calf
serum (Gibco BRL Life Technologies, Waltham, MA, USA), 2 mM
L-glutamine (Sigma Aldrich, St. Louis, MO, USA) and antibiotic
antimycotic solution (Sigma Aldrich, St. Louis, MO, USA) containing
20 units of penicylin, 20 μg streptomycin and 0.05 μg amphotericin
B. HL-60 and U937 cells were grown at 37˚C in a humidified
atmosphere of 95% air and 5% CO2 (HERAcell incubator, KendroLab,
Warsaw, Poland). The cells were passaged every third day and
periodically tested for Mycoplasma infection. 
Chemicals. The bromoalkyl phenytoin derivatives (Figure 1), methyl
2-(1-(3-bromopropyl)-2,4-dioxo-5,5-diphenylimidazolidin-3-yl)
propanoate (PH2), 1-(3-bromopropyl)-3-methyl-5,5-diphenylimida-
zolidine-2,4-dione (PH3) and 1-(4-bromobutyl)-3-methyl-5,5-
diphenylimidazolidine-2,4-dione (PH4) were obtained from
Department of Technology and Biotechnology of Drugs (Jagiellonian
University in Krakow, Poland) using methods previously described
(5). Purity and identity of these compounds were confirmed, using thin
layer chromatography (TLC), spectral methods (1H-NMR and IR),
elemental analysis and melting point measurements. The tested
bromoalkyl phenytoin derivatives were dissolved in dimethyl sulfoxide
(DMSO, Sigma Aldrich, St. Louis, MO, USA) and all solutions were
freshly prepared before treatment of HL-60 and U937 cells. 
Agents concentration and cell treatment. After diluting the cell
suspension to a density of 1.5×105 cells/ml of the complete RPMI
1640 medium, HL-60 and U937 cells were exposed to the action of
the bromoalkyl phenytoin analogs, PH2, PH3, and PH4, at the
concentrations of 50 μM and 100 μM, which were chosen based on
the results of a previous study (6). The control material consisted of
untreated HL-60 and U937 cells and those treated only with 0.4%
DMSO. 
Flow cytometric annexin V-FITC/PI assay. The cell surface exposure
of phosphatidylserine and plasma membrane impairment were
assessed by dual staining of leukemia cells with fluoresceinated
annexin V (annexin V-FITC) and propidium iodide (PI), using
Annexin V-FITC Apoptosis Detection Kit (Becton Dickinson
Pharmingen™, Vienna, Austria). Briefly, the leukemia cell suspension
was centrifuged for 7 min at 100 × g and 4˚C, the supernatant was
removed by aspiration, and the cells were washed in 1 ml of phosphate
buffered saline (PBS, BioMed, Lublin, Poland). After the washing
step, the cell pellet was resuspended in 100 μl of binding buffer. Then
2.5 μl of annexin V-FITC and 2.5 μl of PI solution were added and
the cells were incubated in the dark for 15 min at room temperature.
Following incubation, 400 μl of binding buffer was added into each
cell sample which was placed on ice, away from light. FITC and PI
fluorescence was measured by flow cytometry (Becton Dickinson, San
Jose, CA, USA). 
Flow cytometric CaspGLOW Red Active Caspase assays. The
leukemia cells with active caspase-8 and caspase-9 were detected,
using respectively, CaspGLOW Red Active Caspase-8 Staining Kit
and CaspGLOW Red Active Caspase-9 Staining Kit (Biovision,
Milpiats, CA, USA). The cell suspension was centrifuged for 7 min at
100 × g and 37˚C, and the supernatant was removed by aspiration. The
cell pellet was resuspended in 150 μl of PBS, 0.5 μl of Red-IETD-
FMK or 0.5 μl of Red-LEHD-FMK was added into each sample and
the cells were incubated for 1 h at 37˚C. Then the cells were
centrifuged, the supernatant was removed and the cells were washed
twice in 500 μl of wash buffer. After the washing step, the cells were
resuspended in 300 μl of wash buffer and the cell samples were
immediately analyzed, using flow cytometry (Becton Dickinson, San
Jose, CA, USA).
Flow cytometric CellEvent™ Caspase Green assay. The leukemia
cells with active caspase-3/7 were identified using CellEvent™
Caspase-3/7 Green Flow Cytometry Assay Kit (Molecular Probes,
Eugene, OR, USA). The cell suspension was centrifuged for 7 min at
100 × g and 37˚C, and the supernatant was removed by aspiration. The
cell pellet was resuspended in 500 μl of PBS. Then 0.5 μl of
CellEvent™ Caspase-3/7 Green Detection reagent was added into each
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Figure 1. Chemical structures of three bromoalkyl phenytoin derivatives, PH2, PH3, and PH4.
sample, and the cells were incubated for 30 min at 37˚C. After
incubation, the cells were analyzed by flow cytometry (Becton
Dickinson, San Jose, CA, USA). 
Flow cytometric TMRE test. Mitochondrial membrane potential was
determined using TMRE (tetramethylrhodamine ethyl ester
perchlorate) assay. A TMRE stock solution was prepared at a
concentration of 10 mM in DMSO and stored at −20˚C. The final
concentration of TMRE staining solution used was 100 nM. The
leukemia cell suspensions, containing approximately 2.5-5×105
cells/ml, were centrifuged for 7 min, at 100 × g and 37˚C (MPW-
351RH, Med. Instruments, Warszawa, Poland). Then the cell pellet
was washed twice in 1 ml of warm Hank’s balanced salt solution
(HBSS, Gibco BRL Life Technologies, Waltham, MA, USA). Next,
the cells were resuspended in 100 μl of 100 nM TMRE, and incubated
at 37˚C in the darkness. After 20 min incubation, the cells were
washed with 1 ml of warm HBSS and centrifuged. Next, the
supernatant was discarded, the cells were resuspended in 500 μl of
HBSS, and TMRE fluorescence was immediately detected by flow
cytometry (Becton Dickinson, San Jose, CA, USA).
Flow cytometric APO-BrdU assay. The two-colour staining method
for labelling DNA breaks and total cellular DNA was performed, using
APO-BrdU Kit (Becton Dickinson Pharmingen™, Vienna, Austria).
Briefly, the leukemia cells were fixed in 1% formaldehyde (Polish
Chemical Reagents, S.A., Gliwice, Poland) in PBS, kept in a fridge
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Figure 2. Effects of the bromoalkyl phenytoin derivatives, PH2, PH3, and PH4, on phosphatidylserine externalization and plasma membrane
impairment in HL-60 and U937 cells. Representative dot plots for HL-60 (A) and U937 (B) cells obtained 48 h after application of DMSO only,
and PH2; FL1-H - green fluorescence of FITC; FL2-H - red fluorescence of PI. I - early apoptotic cells with phosphatidylserine externalization
(annexin V-FITC+/PI–); II - late apoptotic and necrotic cells with phosphatidylserine externalization and plasma membrane impairment (annexin
V-FITC+/PI+); III – live cells (annexin V-FITC–/PI–). The frequency of annexin V-FITC+/PI– (C, D), annexin V-FITC+/PI+ (E, F) HL-60 (C, E)
and U937 (D, F) cells observed 24 h and 48 h after their exposure to the action of the tested phenytoin analogs. Values significantly different at
p<0.05 according to the Tukey’s multiple range test: *, **, *** between the groups of leukemia cells treated with the phenytoin derivatives, 
# compared to controls; + between the time points.
for 30 min, and then stored at −20˚C in 80% ethanol until analysis.
The leukemia cell suspension was centrifuged for 7 min at 100 × g
and 80% ethanol was removed by aspiration. Next, the TUNEL
method was performed according to the APO-BrdU protocol described
in detail by Mazur et al. (15). Finally, 300 μl of the PI/RNase solution
was added to the tube containing 100 μl of the antibody solution, and
the cells were incubated in the dark for 30 min at room temperature.
The fluorescence of both FITC conjugated with anti-BrdU and PI was
detected by flow cytometry (Becton Dickinson, San Jose, CA, USA). 
Electron microscopic analysis of cells. The fixation, contrasting and
immersion of HL-60 cells for electron microscopy were performed
according to the modified method described by Marzella and Glauman
(16). Briefly, leukemia cells were fixed in 3% glutaraldehyde (Serva,
Heidelberg, Germany) in 0.1 M cacodylate buffer, fixed and postfixed
in osmium tetroxide (SPI Supplies, West Chester, PA, USA),
dehydrated in increasing series of ethanol (10-99.9 %, Chempur,
Piekary Śląskie, Poland). After dehydratation the cells were placed in
a mixture of alcohol with propylene oxide (Sigma Aldrich, St. Louis,
MO, USA), respectively, in a ratio of 3:1, 1:1, 1:3, pure propylene
oxide and then placed in a mixture propylene oxide and resin, in a
ratio of 3:1 and 1:1. Next, the cells were immersed in Epon 812
(Serva, Heidelberg, Germany), polymerized at 40˚C for 24 h and 60˚C
for the next 24 h. The preparations were cut into ultrathin slices
(ultramicrotome EM UC7, Leica Microsystems, Wetzlar, Germany),
and additionally contrasted in uranyl acetate and lead citrate (SPI
Supplies, West Chester, PA, USA). The analysis of ultramicroscopic
changes was performed using a transmission electron microscope
TECNAI G2 Spirit BioTwin (FEI Company, Oregon, USA).
Statistical evaluation. The flow cytometry data were analyzed using
CellQuest Pro software (Becton Dickinson, San Jose, CA, USA). All
data are presented as the mean values±standard deviation, calculated
from three independent experiments carried out in duplicate or
triplicate. Statistical analyses were performed using STATISTICA 10
(StatSoft, Warszawa, Poland). Data were analyzed by one-way analysis
of variance followed by Tukey’s honestly significant differences
multiple range test. A difference with p<0.05 was considered
statistically significant.
Results 
Cytotoxic effects of bromoalkyl phenytoin derivatives on human
leukemia cells. The influence of PH2, PH3 and PH4, applied
at two concentrations of 50 μM and 100 μM, on HL-60 and
U937 cells, was determined. As shown in Figures 2-7, the
bromoalkyl phenytoin derivatives triggered regulated cell
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Figure 3. Effects of the bromoalkyl phenytoin derivatives, PH2, PH3, and PH4, on activation of caspase-8, -9 and -3/7 in HL-60 and U937 cells.
Representative histograms of HL-60 cells (A, B, C), obtained 24 h after application of DMSO only, and PH3; X axis: (A) fluorescence of Red-IETD-
FMK, a caspase-8 inhibitor IETD-FMK conjugated to sulfo-rhodamine; (B) - fluorescence of Red-LEHD-FMK, a caspase-9 inhibitor LEHD-FMK
conjugated to sulfo-rhodamine, (C) – fluorescence of CellEvent™ Caspase-3/7 Green Detection Reagent, a fluorogenic substrate for activated
caspases-3/7. M1 – HL-60 cells without active caspase-8 (A), -9 (B) and -3/7 (C); M2 - cells with active caspase-8 (A), -9 (B) and -3/7 (C); The
frequency of HL-60 (D, E, F) and U937 (G, H, I) cells with active caspase-8, -9 and -3/7 observed 24 h after after their exposure to the action of
the tested phenytoin analogs. Values significantly different at p<0.05 according to the Tukey’s multiple range test: *, **, *** between the groups of
leukemia cells treated with PH2, PH3, and PH4, # compared to controls.
death, affected cell cycle, and caused ultrastructural changes in
the human leukemia cells.
Influence of PH2, PH3, and PH4 on cell death-induction and
cell-cycle. Using the flow cytometry assays, the influence of
three bromoalkyl derivatives on the frequency of HL-60 and
U937 leukemia cells with phosphatidylserine externalization
and plasma membrane impairment (Figure 2), the percentage
of cells with initiator caspase-8 and -9 activity and executor
caspase-3/7 activity (Figure 3), the frequency of both cells with
dissipated mitochondrial membrane potential (Figure 4) and
cells displaying DNA fragmentation (Figure 5), and also the
percentage of cells in particular phases of the cell cycle (Figure
6), was demonstrated. The obtained results were dependent on
the 5,5-diphenylhydantoin derivative applied, its concentration,
the time intervals after application of the tested agent, and the
human leukemia cell line used. In general, among the
bromoalkyl phenytoin derivatives, the 3-methyl analog with the
bromopropyl chain (PH3) appeared to be the more active in
triggering regulated cell death and cell cycle perturbation than
the ester- (PH2) and bromobutyl- (PH4) analogs, and HL-60
cells were more sensitive to this action of all tested agents than
U937 cells.
Influence of PH2, PH3, and PH4 on human leukemia cell
ultrastructure. Using electron microscopy, the ultrastructural
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Figure 5. Effects of three bromoalkyl phenytoin derivatives, PH2, PH3,
and PH4, on induction of DNA breakage in HL-60 and U937 cells. The
3’OH termini in the strand breaks was analyzed by attaching FITC-
labelled Br-dUTP, in a reaction catalyzed by exogenous TdT, and the
incorporation of Br-dUTP into DNA strand breaks, detected by FITC-
conjugated anti-BrdU antibody. The frequency of TUNEL-positive 
HL-60 (A) and U937 (B) cells observed 24 h after application of the
three tested agents. Values significantly different at p<0.05 according
to the Tukey’s multiple range test: *, **, *** between the groups of
leukemia cells treated with the phenytoin analogs, # compared to
controls.
Figure 4. Effects of the bromoalkyl phenytoin derivatives, PH2, PH3,
and PH4, on mitochondrial membrane potential of HL-60 and U937
cells. Representative dot plots of U937 cells (A) obtained 48 h after
their exposure to DMSO only, and PH2; R1 - cells with the high
mitochondrial membrane potential; R2 - cells with low mitochondrial
membrane potential; FL2-H - fluorescence of TMRE, a cell-permeable,
positively-charged, red-orange dye which readily accumulates in active
mitochondria, and its retention is dependent on mitochondrial
membrane potential. The frequency of HL-60 (B) and U937 (C) cells
with low mitochondrial membrane potential determined 24 h and 48 h
after application of PH2, PH3, and PH4. Values significantly different
at p<0.05 according to the Tukey’s multiple range test: *, **, ***
between the groups of leukemia cells exposed to the action of the tested
phenytoin analogs; # compared to controls; + between the time points.
changes occurring in HL-60 cells after their exposure to the
action of the three bromoalkyl phenytoin analogs, PH2, PH3,
and PH4, were observed (Figure 7). In comparison with the
intact ultrastructure of control HL-60 cells, nuclei with slightly
widened intermembrane space, slightly swollen endoplasmic
reticulum, and a variety of vacuoles were visible after
application of the three tested 5,5-diphenylhydantoin
derivatives, at the concentration of 50 μM. Moreover,
abnormalities in the Golgi apparatus were found after the
exposure of the leukemia cells to the action of PH3 and PH4,
at the same concentration. After application of the bromoalkyl
phenytoin analogs, at the concentration of 100 μM,
considerable alterations in cell ultrastructure, such as
significant swelling of endoplasmic reticulum, the presence of
numerous and varied vacuoles in cytoplasm, with different
degree of degradation of their content, and formation of
vacuoles in intermembrane space of the nucleus, were
observed. The action of PH2 and PH4 resulted in changes in
chromatin distribution in nucleus, distinct matrix condensation
in mitochondria. PH4 application caused abnormalities in the
Golgi apparatus and lysosomes, and PH3 was responsible for
distinct structural disintegration, loss of the plasma membrane
integrity, and uncontrolled release of cytoplasmic content into
the extracellular space. Thus, the ultrastructural alterations
found in the human leukemia HL-60 cells depended on the
bromoalkyl phenytoin analog applied, and its concentration. 
Discussion
In the present investigations, the in vitro cytotoxic effects of
three bromoalkyl phenytoin derivatives, PH2, PH3, and PH4
on human promyelocytic leukemia cells and human
histiocytic lymphoma cells, were assessed. The results of
flow cytometric and electron microscopic analyses
demonstrated that these 5,5-diphenylhydantoin derivatives
triggered regulated cell death, disturbed the cell cycle, and
affected cell ultrastructure. After application of bromoalkyl
phenytoin analogs, plasma membrane diversity and
impairment, activation of the initiator caspase-8 and -9 and
executor caspase-3/7, dissipation of mitochondrial membrane
potential, DNA fragmentation, cell-cycle perturbation, and
ultrastructural changes occurring in the nucleus, endoplasmic
reticulum, Golgi apparatus, mitochondrium, lysosome, and
vacuolar compartments, were found. 
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Figure 6. Effects of three bromoalkyl phenytoin derivatives, PH2, PH3 and PH4, on cell-cycle distribution of HL-60 and U937 cells. Representative
histograms of the cell cycle of HL-60 cells (A) obtained 24 h after their exposure to the action of DMSO only, PH2, PH3, and PH4; X axis - red
fluorescence of PI. The PI/RNase solution was used for staining the total DNA. The frequency of HL-60 (B, C, D) and U937 (E, F, G) cells in the
particular phases of the cell cycle determined 24 h after application of the tested agents. Values significantly different at p<0.05 according to the
Tukey’s multiple range test: *, **, *** between the groups of leukemia cells treated with the three phenytoin analogs, # compared to controls.
It can be generally stated that bromoalkyl phenytoin
derivatives triggered apoptosis, necrosis, and autophagy, and
in the case of intensive processes of autophagy, cells underwent
autophagic death. These tested agents activated caspase-8 and
caspase-9 cascade, respectively, through extrinsic/receptor and
intrinsic/mitochondrial pathways, and caused dysfunction of
cellular compartments that expressed ultrastructural alterations.
Moreover, the 5,5-diphenylhydantoin derivatives distinctly
disturbed the cell-cycle phase distribution. These are the first
data showing the cytotoxic influence of PH2, PH3, and PH4
on HL-60 and U937 cells. It should be emphasized that among
the tested agents, the bromopropyl analog with 3-methyl
substituent (PH3), applied at the concentration of 100 μM, has
the greatest antileukemic activity, and especially against 
HL-60 cells.
Structural modifications of phenytoin were responsible for
the different cytotoxic activities of its bromoalkyl derivatives
against HL-60 and U937 cells. The three bromoalkyl phenytoin
analogs, PH2, PH3, and PH4, differ within two substitution
places at the hydantoin ring, a substituent at position 3, and the
length of the alkyl chain at position 1 of the hydantoin ring.
The analog PH2 has the methylpropanoate substituent at
position 3, while the compounds PH3 and PH4 have only the
methyl group. Among the bromoalkyl phenytoin analogs, PH2
and PH3 have the bromopropyl substituent and PH4 has the
bromobutyl one. The presence of bromopropyl or bromobutyl
substituent at position 1 of hydantoin ring underlines their
alkylating properties (5). Nevertheless, the precise mechanisms
of action of the bromoalkyl phenytoin analogs have not yet
been completely explained, so further studies are needed. 
Little is also known about induction of regulated death and
cell-cycle perturbation in pathological hematopoietic cells by
other hydantoin derivatives. It was reported that novel
derivatives of spirohydantoin caused growth inhibition
followed by apoptosis-induction in leukemia cells (11). It was
also found that the azaspiro hydantoin derivative triggered
apoptosis in human leukemia cells through the mitochondrial
pathway following cell cycle arrest (12). 
Śladowska et al: Antileukemic Activity of Bromoalkyl Phenytoin Analogs
6379
Figure 7. The ultrastructure of HL-60 cells observed 48 h after application of PH2, PH3, and PH4, at the concentration of 50 μM and 100 μM.
Compared to the control cell ultrastructure, changes in the ultrastructure of leukemia cells exposed to the action of the bromoalkyl phenytoin
derivatives including chromatin distribution, perinuclear vacuolization, variety of vacuoles in cytoplasm, mitochondrial abnormalities, swelling of
endoplasmic reticulum, abnormalities in the Golgi apparatus and lysosomes, and plasma membrane impairment, are visible depending on the agent
applied and its concentration. N: Nucleus; M: mitochondria; L: lysosome; ER: endoplasmic reticulum, VA: autophagic vacuole; AG: Golgi apparatus. 
Conclusion 
The findings of the present study clearly indicate that the
bromoalkyl analogs of phenytoin, PH2, PH3, and PH4,
triggered regulated cell death, disturbed cell-cycle distribution,
and caused ultrastructural changes in human promyelocytic
leukemia cells and human histiocytic lymphoma cells. The
antileukemic activity of these three 5,5-diphenylhydantoin
derivatives depended on their structural differences at position
1 and 3 as well as on the cell line. The present study provides
a new insight into the action of bromoalkyl phenytoin analogs
as potential therapeutic agents for pathological hematopoietic
cells.
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